KZIA

MKT CAP:$20M

Kazia Therapeutics Limited

Market Cap

$20M

Healthcare·Biotechnology·🇦🇺 Australia·NASDAQ

Healthcare·Biotechnology·🇦🇺·NASDAQ

Stock Price

$11.82+$6.82 (+136.40%)

Apr 23, 2026

Company Details

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as ...

CEO

John Edwin Friend

IPO Date

Jan 6, 1999

Website

www.kaziatherapeutics.com

Key Metrics TTM

Revenue

$2M

+22633.7% YoY

Net Income

-$35M

EPS (Diluted)

-$42.81

Free Cash Flow

-$13M

Revenue / Share

$0.57

Gross Margin

100.0%

Operating Margin

-1864.0%

Net Margin

-1961.5%

FCF Margin

-746.0%

P/S

11.1x

P/E

—

Earnings Reports

Q2 2026

Mar 19, 2026

$0EPS -$2.82

FY 2025

Nov 7, 2025

$30.0K-98.2%EPS -$13.50

Q4 2025

Nov 7, 2025

$14.1K-99.2%EPS -$4.57

FY 2024

Nov 15, 2024

$2M+415755.9%EPS -$39.28

Q4 2024

Nov 15, 2024

$2M+247999.5%EPS -$22.28

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 17	$3M	-$4M	-$5M
Q2 18	$1M	$1M	-$5M
Q4 18	$1M	-$6M	-$3M
Q2 19	$548.6K	$548.6K	-$4M
Q4 19	$479.7K	-$7M	-$3M
Q2 20	$446.8K	$446.8K	-$4M
Q2 21	$836	$836	-$5M
Q4 21	$11M	$11M	$38.2K
Q2 22	$7.1K	$7.1K	-$10M
Q4 22	$0	$0	-$18M
Q2 23	$0	$0	-$10M
Q4 23	$714	$714	-$8M
Q2 24	$4	$4	-$6M
Q4 24	$2M	$2M	-$14M
Q4 25	$14.1K	$14.1K	-$3M
Q2 26	$0	$0	-$9M

Valuation

Quarter	P/S	P/E
Q4 17	2.1x	—
Q2 18	2.1x	—
Q4 18	2.1x	—
Q2 19	2.4x	—
Q4 19	5.6x	—
Q2 20	11.6x	—
Q2 21	63.7x	—
Q4 21	11.1x	—
Q2 22	10.1x	—
Q4 22	5.3x	—
Q2 23	1.7x	—
Q4 23	3541.1x	—
Q2 24	14025.3x	—
Q4 24	5.2x	—
Q4 25	5.5x	—
Q2 26	5.4x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 17	-$3M	-$3M
Q2 18	-$6M	-$6M
Q4 18	-$574.7K	-$568.2K
Q2 19	-$3M	-$3M
Q4 19	-$2M	-$2M
Q2 20	-$2M	-$2M
Q2 21	-$9M	-$9M
Q4 21	$2M	$2M
Q2 22	-$8M	-$8M
Q4 22	-$8M	-$8M
Q2 23	-$6M	-$6M
Q4 23	-$5M	-$5M
Q2 24	-$5M	-$5M
Q4 24	-$2M	-$2M
Q4 25	-$3M	$0
Q2 26	-$6M	-$6M

Capital Expenditures

Quarter	CapEx
Q4 17	$1.7K
Q2 18	$6.6K
Q4 18	$6.6K
Q2 19	$0
Q4 19	$0
Q2 20	$0
Q2 21	$0
Q4 21	$0
Q2 22	$0
Q4 22	$0
Q2 23	$0
Q4 23	$0
Q2 24	$0
Q4 24	$0
Q4 25	$3M
Q2 26	$4

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 17	+3153.4%	+90.6%
Q2 18	-52.3%	+13.0%
Q4 18	+558.6%	-17.6%
Q2 19	-83.3%	-34.5%
Q4 19	-84.0%	-58.9%
Q2 20	-56.8%	-31.1%
Q2 21	-99.9%	+3.5%
Q4 21	+1876.1%	+161.1%
Q2 22	-98.5%	+203.3%
Q4 22	-100.0%	+302.9%
Q2 23	-100.0%	+111.9%
Q4 23	-100.0%	-30.5%
Q2 24	-99.9%	-34.1%
Q4 24	—	-13.1%
Q4 25	—	-64.3%
Q2 26	-100.0%	+26.6%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 17	$81.5K	2.7%
Q2 18	$35.1K	3.4%
Q4 18	$104.0K	9.4%
Q2 19	$124.8K	22.7%
Q4 19	$51.2K	10.7%
Q2 20	$145.3K	32.5%
Q2 21	$218.0K	26094.0%
Q4 21	$236.4K	2.2%
Q2 22	$457.7K	6409.1%
Q4 22	$738.2K	—
Q2 23	$674.7K	—
Q4 23	$153.1K	21439.9%
Q2 24	$311.7K	8729300.0%
Q4 24	$68.9K	3.9%
Q4 25	$0	0.0%
Q2 26	$0	—

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q4 17	$4M	$3M	—	—
Q2 18	$3M	$3M	—	—
Q4 18	$4M	$815.4K	—	—
Q2 19	$3M	$1M	—	—
Q4 19	$2M	$1M	—	—
Q2 20	$3M	$2M	—	—
Q2 21	$2M	$3M	—	—
Q4 21	$8M	$2M	—	—
Q2 22	$8M	$2M	—	—
Q4 22	$7M	$2M	$90.7K	—
Q2 23	$7M	$3M	—	—
Q4 23	$4M	$3M	—	—
Q2 24	$3M	$3M	—	—
Q4 24	$9M	$6M	—	—
Q4 25	$2M	—	—	$3M
Q2 26	$3M	—	—	$6M

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 18	$4M	$0	$4M
Q2 19	$4M	$0	$4M
Q4 19	$4M	$0	$4M
Q2 20	$5M	$0	$5M
Q4 20	$6M	$0	$6M
Q2 21	$14M	$0	$14M
Q4 21	$20M	$0	$20M
Q2 22	$11M	$0	$11M
Q4 22	$5M	$0	$5M
Q2 23	$3M	$0	$3M
Q4 23	$4M	$0	$4M
Q2 24	$3M	$0	$3M
Q4 24	$1M	$0	$1M
Q2 25	$2M	$0	$2M
Q4 25	$3M	$0	$3M
Q2 26	$50M	$0	$50M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 17	101K	+6.8%	+67.8%
Q2 18	101K	+0.0%	+18.6%
Q4 18	101K	+0.1%	+12.7%
Q2 19	110K	+9.3%	+16.9%
Q4 19	130K	+17.5%	+28.6%
Q2 20	137K	+5.3%	+35.5%
Q2 21	215K	+57.2%	+112.6%
Q4 21	264K	+22.9%	+139.1%
Q2 22	264K	0.0%	+103.5%
Q4 22	266K	+0.8%	+94.6%
Q2 23	291K	+9.5%	+35.7%
Q4 23	456K	+56.5%	+72.7%
Q2 24	480K	+5.2%	+81.7%
Q4 24	575K	+19.9%	+116.2%
Q4 25	2M	+170.1%	+433.1%
Q2 26	3M	+100.9%	+584.3%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 17	$187.5K	16
Q2 18	$64.7K	16
Q4 18	$222.1K	5
Q2 19	$109.7K	5
Q4 19	$95.9K	5
Q2 20	$89.4K	5
Q2 21	$167	5
Q4 21	$2M	6
Q2 22	$1.2K	6
Q4 22	$0	9
Q2 23	$0	9
Q4 23	$89	8
Q2 24	$0	8
Q4 24	$295.3K	6
Q4 25	$2.3K	6
Q2 26	$0	6

Revenue / Employee